PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology
BOSTON, Nov. 22, 2011 /PRNewswire/ -- PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has enhanced its central nervous system (CNS) capabilities for clinical development through the implementation of functional magnetic resonance imaging (fMRI) technology in its Early Phase units. This advanced imaging scanning measures hemodynamic response, or change in blood flow, related to neural activity in the brain or spinal cord. Through this approach, PAREXEL is able to provide sponsors with improved testing paradigms for cognitive biomarkers and better understand the impact of compounds earlier in disease progression.
PAREXEL is among the first to apply this technology broadly to multicenter trials with centralized imaging review processes to improve the quality, consistency and reproducibility of clinical data. This advancement is part of PAREXEL's long-standing commitment to the CNS therapeutic area. The Company has focused on bringing extensive expertise and the latest innovations to early phase drug development, making it a premier provider to biopharmaceutical companies worldwide.
"PAREXEL has continued to provide clients with true leadership in early phase CNS drug development—combining the latest technology with our extensive scientific expertise and CNS research tools, including cerebrospinal fluid dynabridging studies," said Larry Ereshefsky, Pharm. D., F.C.C.P, B.C.P.P., Vice President and Principal Consultant, Early Phase, PAREXEL.
According to Dr. Ereshefsky, "We are helping the biopharmaceutical industry take a major step forward to leverage a